#United States #North Chicago #Allergan Aesthetics #TrenibotulinumtoxinE #BOTOX®

Allergan Aesthetics Showcases Research Innovations at AMWC 2026

Allergan Aesthetics, a prominent entity within AbbVie, is making waves in the aesthetic medicine field with a significant showcase of research at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2026, held in Monaco between March 26-28, 2026. The company presented 21 evidence-based e-posters, highlighting their commitment to advancing patient-centric innovations in aesthetics.

The collection of e-posters spans various research dimensions—clinical, real-world, and preclinical data—reflecting a robust dedication to achieving superior results for patients worldwide. Among the most notable presentations were five studies focusing on trenibotulinumtoxinE (commonly referred to as TrenibotE), which demonstrated an impressive rapid onset of results, achieving visible improvements in glabellar lines within just 8 hours of treatment.

Key Findings on TrenibotE

The e-posters detailing TrenibotE reveal several significant findings:
1. Rapid Results and Safety: Patients treated with TrenibotE showed a rapid and consistent enhancement in moderate to severe glabellar lines shortly after treatment. The observed efficacy remained consistent across diverse populations, including East Asian and North American/European individuals.
2. High Satisfaction Rates: Throughout the evaluations, treatments delivered high patient satisfaction characterized by natural-looking results and notable improvements in psychosocial measures following procedures.
3. Effective with Various Treatment Histories: Notably, TrenibotE proved effective for both toxin-naïve patients and those with prior experience using onabotulinumtoxinA (popularly known as BOTOX® Cosmetic), reinforcing its versatility and reliability.

Additionally, early evidence suggests that administering TrenibotE sequentially with onabotulinumtoxinA may enhance treatment outcomes for glabellar lines, providing practitioners with a well-rounded approach to facial aesthetics.

Reinforcing BOTOX® Cosmetic Leadership

Further solidifying its position in the market, Allergan Aesthetics shared insights concerning its flagship product, BOTOX® Cosmetic. Recent studies reveal that long-term treatment with BOTOX leads to high satisfaction rates—from improved appearance to enhanced psychological well-being. Importantly, the data indicated that patients who begin with BOTOX often pursue additional aesthetic treatments, establishing a relationship with multi-modal aesthetic approaches.

This aspect of continuity in patient care suggests that BOTOX serves as not just a standalone treatment, but as a gateway to broader aesthetic enhancements, which is crucial for practitioners aiming to meet evolving patient needs.

Innovative Hyaluronic Acid Treatments

Allergan Aesthetics also revealed findings on its Hyaluronic Acid (HA) injectables, namely VYC-12L and VYC-20L. Clinical data showcased how these products effectively improve skin quality across multiple facial regions, including neck lines and perioral areas, achieving enduring results for up to six months. Observations indicate patients experienced significant improvements in skin smoothness, highlighting the products’ effectiveness and safety across varied demographics.

Commitment to Integrated Aesthetic Solutions

Collectively, the presentations underscore Allergan Aesthetics' leadership in neurotoxin and integrated facial aesthetic strategies. With comprehensive scientific evidence backing their innovative offerings, practitioners attending AMWC gained invaluable insights on enhancing their treatment practices.

These studies are accessible via the AMWC app and at specified locations within the venue, reflecting Allergan Aesthetics' commitment to transparency and education in the field of aesthetic medicine.

As evidenced by these presentations, Allergan Aesthetics remains dedicated to delivering safe, effective, and tailored treatment solutions that enable practitioners to achieve their aesthetic goals with utmost confidence. The AMWC 2026 serves not only as a platform for showcasing advances in aesthetic treatments but also as a reaffirmation of Allergan's position as a leader committed to enhancing patient experiences in aesthetics medicine.